Updated on 16 October 2013
OncoCyte has partnered with Wistar Institute to collaboratively develop lung cancer diagnostic products
Singapore: BioTime's subsidiary OncoCyte Corporation has entered into a Sponsored Research Agreement and a Material Transfer Agreement with Wistar Institute to collaboratively develop lung cancer diagnostic products.
As part of the collaboration, Wistar investigators are conducting a multi-center patient study in which they are assessing gene expression patterns in blood cells of patients with malignant versus non-malignant lung disease.
OncoCyte scientists will analyze blood samples obtained from patients in the study to determine levels of tumor-associated proteins using its proprietary PanC-Dx diagnostic tests. PanC-Dx is a class of non-invasive cancer diagnostics based on a proprietary set of cancer markers characterized, in part, by broad gene expression patterns in numerous cancer types.
The inclusion of the PanC-Dx markers in Wistar's ongoing multi-center study may allow OncoCyte to more rapidly develop a diagnostic test for lung cancer to be marketed in the U.S. and other countries.
The performance of markers tested in the study in determining the presence or the progression of disease in various categories of patients may determine the specific nature of the lung cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue. OncoCyte will have an option to exclusively license any inventions, discoveries or technology developed by Wistar, or by OncoCyte using Wistar technology, in the course of the collaborative research.